Gland Pharma gets USFDA’s tentative nod for Brimonidine Tartrate Ophthalmic Solution

04 Mar 2026 Evaluate

Gland Pharma has secured tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC).  

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Lumify Ophthalmic Solution, 0.025%, of Bausch & Lomb Inc. It is indicated to relieve redness of the eye.

According to IQVIA, the product had US sales of around $39 million for the twelve months ending September 2025.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

Gland Pharma Share Price

1607.00 9.75 (0.61%)
20-Mar-2026 13:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1773.40
Dr. Reddys Lab 1294.50
Cipla 1256.00
Zydus Lifesciences 889.70
Lupin 2318.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×